[{"orgOrder":0,"company":"University of Iowa Pharmaceuticals","sponsor":"Shuttle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"||DNA synthesis","graph1":"Oncology","graph2":"Phase II","graph3":"University of Iowa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Iowa Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Iowa Pharmaceuticals \/ University of Iowa Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by University of Iowa Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The agreement aims at the formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. Ropidoxuridine is used to sensitize rapidly growing cancer cells and selective histone deacetylase inhibitors to sensitize cancer cells.

                          Product Name : IPdR Prodrug

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 03, 2023

                          Lead Product(s) : Ropidoxuridine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Shuttle Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank